Artificial Intelligence Applied to Clinical Practice

Submitted by Catalina on 13 April 2026 - 9:11

The EFIM Multimorbidity Working Group is pleased to invite you to our upcoming webinar, “Artificial Intelligence Applied to Clinical Practice,” taking place on, 11 June 2026, from 17:00 to 18:00 CET. This session will address key aspects of artificial intelligence in the context of clinical practice, featuring: Chair: Edouard Battegay.  Join us for this insightful session and engage with experts.

Register here: https://us02web.zoom.us/webinar/register/WN_P3SGHzu8T8SFo0pRPfDjUw

 

 

Orphan designation: 2-[[(4-Methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-ol Treatment of multiple system atrophy, 09/01/2026 Positive

Submitted by Anonymous (not verified) on 10 April 2026 - 15:21

Orphan designation: 2-[[(4-Methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-ol Treatment of multiple system atrophy, 09/01/2026 Positive

Orphan designation: N-[5-(2H-1,3-Benzodioxol-5-yl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]-N'-(2-methoxyethyl)sulfuric diamide Treatment of primary IgA nephropathy, 09/01/2026 Positive

Submitted by Anonymous (not verified) on 10 April 2026 - 15:21

Orphan designation: N-[5-(2H-1,3-Benzodioxol-5-yl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]-N'-(2-methoxyethyl)sulfuric diamide Treatment of primary IgA nephropathy, 09/01/2026 Positive

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 32, Status: Authorised

Submitted by Anonymous (not verified) on 10 April 2026 - 15:00

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 32, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More